Survival of metastatic cancer and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies.-Reference-Cited by-同舟云学术

Survival of metastatic cancer and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies.

Published:2021-04-11 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

CABRAS MARCO^ORCID,Gambino Alessio^ORCID,CONROTTO DAVIDE,Garrone Marco,Fasciolo Antonella,basano lorenzo,Gilardetti Marco,galassi claudia,Fusco Vittorio

Publisher

Qeios Ltd

Reference14 articles.

1. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma

2. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid

3. Single‐center analysis of antiresorptive agent‐related osteonecrosis of the jaw in lung cancer patients

4. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents

5. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence;Clinical and Experimental Medicine;2023-10-07

2. Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points;Supportive Care in Cancer;2022-11-01

3. Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points;Supportive Care in Cancer;2022-07-27

4. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ);Supportive Care in Cancer;2022-03-21

5. SURVIVAL OF MYELOMA PATIENTS RECEIVING BISPHOSPHONATES IN A "REAL LIFE" EXPERIENCE: POTENTIAL IMPACT ON RISK OF OSTEONECROSIS OF THE JAW (ONJ);Qeios;2021-05-01